TAK
Takeda Pharmaceutical·NYSE
--
--(--)
--
--(--)
TAK fundamentals
During Q3 2026, Takeda Pharmaceutical (TAK) reported revenue of 7.60B, a YoY change of 4.54%. Net income was 661.56M, a YoY change of 336.80%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2018 | Q3,2019 | Q4,2019 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | Q1,2026 | Q2,2026 | Q3,2026 | TTM |
|---|
Start Date | Jan 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Oct 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2018 | Dec 31, 2018 | Mar 31, 2019 | Dec 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | -- |
Revenue | 3.78B -- | 4.55B -- | 6.48B +71.63% | 7.91B +73.70% | 7.18B +10.75% | 7.44B -- | 7.47B -- | 8.11B +2.55% | 6.96B -2.96% | 8.55B +14.93% | 7.58B +1.40% | 7.83B -3.49% | 7.19B +3.26% | 7.17B -16.19% | 6.93B -8.59% | 8.32B +6.30% | 7.20B +0.16% | 7.33B +2.24% | 6.98B +0.78% | 7.89B -5.22% | 6.95B -3.52% | 7.51B +2.47% | 8.21B +17.61% | 7.27B -7.80% | 7.03B +1.12% | 7.68B +2.23% | 7.52B -8.40% | 7.60B +4.54% | 29.82B -- |
Sales and Services Revenue | 3.78B -- | 4.55B -- | 6.48B +71.63% | 7.91B +73.70% | 7.18B +10.75% | 7.44B -- | 7.47B -- | 8.11B +2.55% | 6.96B -2.96% | 8.55B +14.93% | 7.58B +1.40% | 7.83B -3.49% | 7.19B +3.26% | 6.29B -26.42% | 6.93B -8.59% | 8.32B +6.30% | 7.20B +0.16% | 7.33B +16.45% | 6.98B +0.78% | 7.89B -5.22% | 6.95B -3.52% | 7.51B +2.47% | 8.21B +17.61% | 7.27B -7.80% | -- -- | 7.68B +2.23% | 7.52B -8.40% | 7.60B +4.54% | -- -- |
Other Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 874.79M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | 1.04B -- | 1.26B -- | 2.55B +143.90% | 2.57B +103.75% | 2.31B -9.37% | 2.21B -- | 2.36B -- | 2.45B -4.65% | 2.29B -0.72% | 2.17B -1.65% | 2.47B +4.61% | 2.44B -0.40% | 2.54B +10.82% | 2.16B -0.65% | 2.11B -14.67% | 2.55B +4.32% | 2.33B -8.11% | 2.22B +2.98% | 2.30B +8.93% | 2.69B +5.65% | 2.53B +8.40% | 2.41B +8.21% | 2.75B +19.72% | 2.65B -1.63% | 2.55B +0.77% | 2.67B +10.93% | 2.57B -6.69% | 2.56B -3.42% | 10.34B -- |
Cost of Goods and Services | 4.67B -- | -- -- | 5.89B +26.10% | -- -- | 10.13B +72.11% | -- -- | -- -- | -- -- | 8.99B -11.30% | -- -- | -- -- | -- -- | 9.11B +1.39% | 2.16B -- | 2.11B -- | 2.55B -- | 2.33B -74.40% | 2.22B +2.98% | 2.30B +8.93% | 2.69B +5.65% | 2.53B +8.40% | 2.41B +8.21% | 2.75B +19.72% | 2.65B -1.63% | -- -- | 2.67B +10.93% | 2.57B -6.69% | 2.56B -3.42% | -- -- |
Gross Profit | 2.73B -- | 3.29B -- | 3.93B +44.00% | 5.33B +62.17% | 4.87B +23.78% | 5.23B -- | 5.11B -- | 5.66B +6.01% | 4.67B -4.03% | 6.38B +21.93% | 5.10B -0.09% | 5.38B -4.83% | 4.65B -0.44% | 5.01B -21.48% | 4.82B -5.64% | 5.77B +7.21% | 4.87B +4.67% | 5.10B +1.93% | 4.68B -2.79% | 5.19B -10.02% | 4.42B -9.23% | 5.10B -0.03% | 5.46B +16.58% | 4.62B -11.00% | -- -- | 5.01B -1.87% | 4.95B -9.26% | 5.04B +9.10% | -- -- |
Other Operating Income | 1.60B -- | -- -- | 1.44B -9.46% | -- -- | 559.96M -61.23% | -- -- | -- -- | -- -- | 2.88B +413.45% | -- -- | -- -- | -- -- | 355.10M -87.65% | 40.38M -- | 55.26M -- | 24.28M -- | 65.90M -81.44% | 29.42M -27.13% | 37.94M -31.34% | 6.34M -73.87% | 56.94M -13.59% | 67.55M +129.58% | 21.40M -43.61% | 14.58M +129.78% | -- -- | 152.81M +126.20% | 10.06M -52.97% | -5.43M -137.28% | -- -- |
Operating Expenses | 5.08B -- | 2.26B -- | 5.80B +14.07% | 4.84B +113.84% | 6.01B +3.56% | 3.68B -- | 4.65B -- | 4.27B -11.85% | 6.19B +3.00% | 4.14B +12.54% | 4.23B -9.05% | 4.37B +2.40% | 5.02B -18.86% | 3.94B -4.85% | 4.15B -1.90% | 4.68B +7.06% | 4.27B -14.98% | 3.97B +0.71% | 5.05B +21.70% | 4.45B -4.81% | 4.54B +6.45% | 4.14B +4.27% | 4.19B -16.97% | 4.21B -5.47% | -- -- | 3.88B -6.20% | 4.50B +7.24% | 3.96B -5.96% | -- -- |
Selling, General and Administrative Expenses | 804.34M -- | 1.69B -- | 1.72B +114.02% | 3.25B +92.70% | -707.62M -141.11% | 2.85B -- | 3.03B -- | 3.12B -3.94% | -661.62M +6.50% | 2.91B +2.12% | 2.82B -6.90% | 3.03B -2.88% | -825.12M -24.71% | 1.71B -41.29% | 1.72B -39.11% | 1.99B -34.36% | 1.92B +332.62% | 1.72B +0.67% | 1.69B -1.52% | 1.90B -4.60% | 1.89B -1.73% | 1.68B -2.27% | 1.87B +10.64% | 1.72B -9.43% | -- -- | 1.77B +5.75% | 1.71B -8.51% | 1.80B +4.89% | -- -- |
Research and Development Expenses | 835.99M -- | 706.12M -- | 1.26B +50.66% | 1.13B +59.92% | 1.30B +2.86% | 991.19M -- | 1.12B -- | 1.14B +0.90% | 1.02B -20.94% | 1.10B +11.27% | 1.18B +5.46% | 1.11B -2.16% | 1.18B +15.47% | 1.06B -4.04% | 1.07B -9.75% | 1.32B +18.85% | 1.21B +2.51% | 1.13B +6.44% | 1.23B +15.56% | 1.33B +0.37% | 1.30B +6.83% | 1.05B -7.04% | 1.23B -0.44% | 1.08B -18.67% | -- -- | 998.06M -4.69% | 1.09B -10.95% | 1.12B +3.33% | -- -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 967.48M -- | 983.80M -- | 1.03B -- | -3.08B -- | 895.85M -7.40% | 1.61B +63.42% | 974.58M -5.25% | -3.35B -8.76% | 1.01B +12.98% | 994.16M -38.16% | 857.30M -12.03% | -- -- | 913.07M -9.79% | 1.39B +39.46% | 905.06M +5.57% | -- -- |
Other Operating Expenses | 3.44B -- | -127.92M -- | 2.82B -18.16% | 463.67M +462.46% | 5.42B +92.22% | -157.35M -- | 499.42M -- | 7.63M -98.36% | 5.82B +7.49% | 131.83M +183.78% | 226.57M -54.63% | 224.56M +2844.44% | 4.66B -19.94% | 207.69M +57.54% | 381.29M +68.29% | 335.97M +49.61% | 4.22B -9.52% | 227.78M +9.67% | 517.83M +35.81% | 251.53M -25.13% | 4.71B +11.75% | 399.38M +75.34% | 99.72M -80.74% | 552.25M +119.55% | -- -- | 194.64M -51.26% | 304.39M +205.24% | 133.60M -75.81% | -- -- |
Operating Income | -757.99M -- | 1.03B -- | -422.25M +44.29% | 492.42M -51.97% | -577.85M -36.85% | 1.55B -- | 457.50M -- | 1.39B +181.70% | 1.36B +335.53% | 2.24B +44.19% | 873.78M +90.99% | 1.01B -27.09% | -13.33M -100.98% | 1.11B -50.44% | 721.70M -17.41% | 1.12B +10.26% | 667.13M +5104.12% | 1.17B +5.19% | -330.19M -145.75% | 744.49M -33.24% | -66.58M -109.98% | 1.03B -11.40% | 1.29B +489.53% | 425.38M -42.86% | -- -- | 1.28B +23.83% | 466.28M -63.75% | 1.08B +153.11% | -- -- |
Non-Operating Income (Loss) | 92.39M -- | -591.29M -- | -307.48M -432.80% | -263.82M +55.38% | -508.01M -65.22% | -343.27M -- | -502.30M -- | -323.14M -22.49% | -177.76M +65.01% | -230.29M +32.91% | -322.70M +35.76% | -384.57M -19.01% | -431.73M -142.87% | 36.53M +115.86% | -275.64M +14.58% | -302.23M +21.41% | -306.19M +29.08% | -232.15M -735.46% | -312.11M -13.23% | -309.78M -2.50% | -247.67M +19.11% | -184.77M +20.41% | -452.87M -45.10% | -257.58M +16.85% | -- -- | -235.39M -27.39% | -275.87M +39.08% | -222.94M +13.45% | -- -- |
Income (Loss) from Affiliates | 10.75M -- | -437.47M -- | 3.01M -72.02% | -176.03M +59.76% | -82.67M -2847.57% | -90.55M -- | 7.80M -- | 8.93M +105.08% | 73.13M +188.47% | -3.21M +96.45% | -28.41M -464.05% | -15.02M -268.12% | -83.27M -213.86% | -3.66M -13.94% | -6.01M +78.86% | -13.41M +10.76% | -41.41M +50.27% | -2.89M +21.01% | 13.55M +325.67% | 7.98M +159.55% | 24.75M +159.76% | -4.43M -52.96% | -3.73M -127.56% | -12.40M -255.37% | -- -- | -3.72M +15.99% | -14.05M -276.20% | 5.10M +141.08% | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -8.97K -- | -- -- | -- -- | -14.74K -- | 13.82K +254.10% | -- -- | -- -- | -- -- | -6.69K -148.42% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -81.64M -- | 153.82M -- | 310.49M +480.32% | 87.79M -42.93% | 425.34M +36.99% | 252.71M -- | 510.11M -- | 332.08M +278.27% | 250.89M -41.01% | 227.08M -10.14% | 294.28M -42.31% | 369.55M +11.28% | 348.46M +38.89% | -40.21M -117.71% | 269.65M -8.37% | 288.82M -21.84% | 264.78M -24.01% | 229.25M +670.15% | 325.66M +20.77% | 317.76M +10.02% | 272.42M +2.88% | 180.35M -21.33% | 449.13M +37.92% | 245.18M -22.84% | -- -- | 231.67M +28.46% | 261.82M -41.70% | 228.04M -6.99% | -- -- |
Interest Expense | 86.32M -- | 203.05M -- | 377.40M +337.22% | 402.48M +98.21% | 381.76M +1.16% | 434.68M -- | 604.98M -- | 607.32M +50.90% | 680.25M +78.19% | 639.96M +47.22% | 355.84M -41.18% | 405.54M -33.22% | 189.95M -72.08% | 408.79M -36.12% | 371.80M +4.49% | 605.03M +49.19% | 323.41M +70.26% | 412.37M +0.88% | 388.29M +4.44% | 477.78M -21.03% | 312.04M -3.52% | 371.03M -10.03% | 477.86M +23.07% | 200.78M -57.98% | -- -- | 743.28M +100.33% | 561.86M +17.58% | 788.44M +292.70% | -- -- |
Interest Income | 167.96M -- | 49.23M -- | 66.91M -60.16% | 314.69M +539.16% | -43.58M -165.13% | 181.97M -- | 94.88M -- | 275.24M -12.54% | 429.36M +1085.25% | 412.89M +126.90% | 61.56M -35.11% | 35.99M -86.92% | -158.51M -136.92% | 449.00M +8.75% | 102.15M +65.93% | 316.21M +778.58% | 58.63M +136.99% | 183.12M -59.22% | 62.63M -38.69% | 160.02M -49.39% | 39.62M -32.42% | 190.68M +4.13% | 28.73M -54.12% | -44.40M -127.75% | -- -- | 511.60M +168.30% | 300.03M +944.21% | 560.40M +1362.03% | -- -- |
Pretax Income From Continuing Operations | -665.59M -- | 433.90M -- | -729.73M -9.64% | 228.60M -47.32% | -1.09B -48.80% | 1.21B -- | -44.80M -- | 1.06B +365.45% | 1.18B +208.97% | 2.01B +66.08% | 551.09M +1330.12% | 626.84M -41.09% | -445.05M -137.61% | 1.15B -42.94% | 446.06M -19.06% | 812.94M +29.69% | 360.94M +181.10% | 934.68M -18.43% | -642.31M -244.00% | 435.00M -46.49% | -314.26M -187.07% | 849.10M -9.16% | 833.31M +229.74% | 167.80M -61.42% | -715.80M -127.78% | 1.04B +23.05% | 190.40M -77.15% | 853.72M +408.77% | 1.37B -- |
Income Tax Expense | -157.31M -- | 88.74M -- | -465.25M -195.76% | 524.05M +490.53% | -1.10B -136.51% | 443.28M -- | -83.35M -- | 168.21M -67.90% | -599.10M +45.56% | 767.69M +73.19% | 138.58M +266.27% | 124.80M -25.81% | -351.38M +41.35% | 371.82M -51.57% | 19.47M -85.95% | -91.01M -172.93% | 126.40M +135.97% | 315.82M -15.06% | -321.28M -1750.43% | -315.78M -246.98% | -294.46M -332.97% | 256.74M -18.71% | 190.34M +159.24% | 16.34M +105.18% | -28.03M +90.48% | 182.78M -28.81% | 269.67M +41.68% | 192.16M +1075.76% | 616.58M -- |
Current Income Tax | 355.54M -- | -- -- | 556.61M +56.56% | -- -- | 2.22B +299.07% | -- -- | -- -- | -- -- | 1.19B -46.29% | -- -- | -- -- | -- -- | 1.72B +43.93% | -- -- | -- -- | -- -- | 1.86B +8.18% | -- -- | -- -- | -- -- | 709.89M -61.78% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | -68.37M -- | -- -- | -624.09M -812.80% | -- -- | -3.20B -412.46% | -- -- | -- -- | -- -- | -1.28B +59.89% | -- -- | -- -- | -- -- | -1.12B +12.63% | -- -- | -- -- | -- -- | -1.42B -26.71% | -- -- | -- -- | -- -- | -1.31B +7.45% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Items Before Net Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -7.53K -- | -- -- | -- -- | -- -- | -6.61K +12.21% | 6.22K -- | -6.98K -- | -- -- | -- -- | 6.94K +11.59% | -6.76K +3.19% | -- -- | -- -- |
Net Income | -508.29M -- | 345.16M -- | -264.48M +47.97% | -295.44M -185.60% | 14.53M +105.49% | 765.70M -- | 38.55M -- | 895.80M +403.21% | 1.78B +12169.81% | 1.24B +61.97% | 412.51M +970.10% | 502.04M -43.96% | -93.67M -105.26% | 773.98M -37.59% | 426.59M +3.41% | 903.95M +80.05% | 234.54M +350.39% | 618.86M -20.04% | -321.02M -175.25% | 750.78M -16.94% | -19.80M -108.44% | 592.36M -4.28% | 642.98M +300.29% | 151.46M -79.83% | -687.78M -3373.81% | 862.03M +45.52% | -79.27M -112.33% | 661.56M +336.80% | 756.55M -- |
Net Income Attributable to Minority Interests | 376.65K -- | 893.35K -- | -280.09K -174.36% | 1.06M +18.46% | -1.51M -437.89% | 74.23K -- | 312.56K -- | 765.58K -27.66% | 415.88K +127.60% | 387.21K +421.62% | 278.03K -11.05% | 442.82K -42.16% | -139.99K -133.66% | 51.59K -86.68% | -69.10K -124.86% | 166.91K -62.31% | 15.07K +110.76% | 76.14K +47.59% | 394.83K +671.36% | 255.46K +53.06% | 158.71K +953.43% | 317.01K +316.34% | 425.83K +7.85% | 292.30K +14.42% | -- -- | 249.71K -21.23% | 486.59K +14.27% | 599.49K +105.09% | -- -- |
Net Income Attributable to Owners of the Company | -508.66M -- | 344.27M -- | -264.20M +48.06% | -296.50M -186.13% | 16.03M +106.07% | 765.62M -- | 38.24M -- | 895.04M +401.86% | 1.78B +11014.25% | 1.24B +61.94% | 412.22M +978.09% | 501.60M -43.96% | -93.53M -105.25% | 773.93M -37.58% | 426.66M +3.50% | 903.78M +80.18% | 234.53M +350.76% | 618.78M -20.05% | -321.42M -175.33% | 750.21M -16.99% | -19.96M -108.51% | 592.04M -4.32% | 642.55M +299.91% | 151.17M -79.85% | -- -- | 861.78M +45.56% | -79.76M -112.41% | 660.97M +337.25% | -- -- |
Other Adjustments | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 9.00K -- | -- -- | -8.68K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -508.66M -- | 344.27M -- | -264.20M +48.06% | -296.50M -186.13% | 16.03M +106.07% | 765.62M -- | 38.24M -- | 895.04M +401.86% | 1.78B +11014.25% | 1.24B +61.94% | 412.22M +978.09% | 501.61M -43.96% | -93.53M -105.25% | 773.93M -37.58% | 426.66M +3.50% | 903.78M +80.18% | 234.53M +350.76% | 618.78M -20.05% | -321.42M -175.33% | 750.21M -16.99% | -19.96M -108.51% | 592.04M -4.32% | 642.55M +299.91% | 151.17M -79.85% | -- -- | 861.78M +45.56% | -79.76M -112.41% | 660.97M +337.25% | -- -- |
Other Comprehensive Income | -635.56M -- | -923.33M -- | 62.32M +109.81% | 1.02B +210.65% | -1.46B -2441.20% | 136.76M -- | -349.36M -- | 121.80M -88.08% | 2.99B +304.98% | 533.80M +290.31% | 244.74M +170.05% | 1.14B +833.38% | 3.10B +3.73% | 5.01B +838.25% | 2.19B +795.76% | -4.04B -455.37% | 981.01M -68.38% | 4.18B -16.46% | 1.20B -45.34% | -- -- | 3.42B +248.54% | 3.51B -16.09% | -6.93B -678.02% | 3.89B -- | -2.33B -168.27% | -35.92M -101.02% | 1.74B +125.17% | 3.50B -9.79% | 2.88B -- |
Total Comprehensive Income | -1.14B -- | -578.17M -- | -202.16M +82.33% | 726.19M +225.60% | -1.44B -614.59% | 902.46M -- | -310.81M -- | 1.02B +40.13% | 4.77B +430.42% | 1.77B +96.58% | 657.25M +311.46% | 1.64B +61.06% | 3.01B -36.97% | 5.78B +225.95% | 2.62B +298.46% | -3.14B -291.36% | 1.22B -59.60% | 4.80B -16.94% | 877.27M -66.50% | -- -- | 3.40B +179.66% | 4.10B -14.57% | -6.28B -816.25% | 4.04B -- | -3.02B -188.90% | 826.12M -79.87% | 1.66B +126.49% | 4.17B +3.21% | 3.63B -- |
Total Comprehensive Income Attributable to Minority Interests | 2.07M -- | 847.77K -- | -90.35K -104.36% | 1.63M +92.13% | -1.34M -1382.18% | 695.93K -- | 909.26K -- | -213.20K -113.09% | 587.65K +143.88% | 441.24K -36.60% | 367.71K -59.56% | 573.07K +368.79% | 90.58K -84.59% | 339.01K -23.17% | 62.19K -83.09% | -303.47K -152.96% | 218.46K +141.18% | 401.47K +18.42% | 414.91K +567.13% | 28.38K +109.35% | 324.03K +48.33% | 459.97K +14.57% | 195.46K -52.89% | 470.23K +1556.62% | -- -- | 173.41K -62.30% | 486.59K +148.94% | 988.52K +110.22% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -1.15B -- | -579.02M -- | -202.07M +82.37% | 724.56M +225.14% | -1.44B -614.24% | 901.76M -- | -311.72M -- | 1.02B +40.47% | 4.77B +430.68% | 1.77B +96.68% | 656.88M +310.73% | 1.64B +60.97% | 3.01B -36.96% | 5.78B +226.01% | 2.62B +298.67% | -3.14B -291.40% | 1.22B -59.61% | 4.80B -16.94% | 876.85M -66.52% | -1.42B +54.78% | 3.40B +179.68% | 4.10B -14.57% | -6.28B -816.62% | 4.04B +384.66% | -- -- | 825.94M -79.87% | 1.66B +126.48% | 4.17B +3.20% | -- -- |
Basic EPS | -- -- | 0.44 -- | -0.17 -- | -0.19 -143.18% | 0.01 +105.88% | 0.49 -- | 0.02 -- | 0.57 +400.00% | 1.14 +11300.00% | 0.79 +61.22% | 0.26 +1200.00% | 0.32 -43.86% | -0.06 -105.26% | 0.5 -36.71% | 0.27 +3.85% | 0.58 +81.25% | 0.15 +350.00% | 0.4 -20.00% | -0.2 -174.07% | 0.48 -17.24% | -0.01 -106.67% | 0.38 -5.00% | 0.41 +305.00% | 0.1 -79.17% | -0.44 -4300.00% | 0.55 +44.74% | -0.05 -112.20% | 0.42 +320.00% | 0.48 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0.5 -- | 0.27 -- | 0.58 -- | -- -- | 0.4 -20.00% | -0.21 -177.78% | 0.48 -17.24% | -- -- | 0.38 -5.00% | -- -- | -- -- | -- -- | 0.55 +44.74% | -- -- | -- -- | -- -- |
Diluted EPS | -- -- | 0.44 -- | -- -- | -0.19 -143.18% | -- -- | 0.49 -- | 0.02 -- | 0.57 +400.00% | -- -- | 0.79 +61.22% | -- -- | -- -- | -- -- | 0.5 -36.71% | 0.27 -- | 0.58 -- | -- -- | 0.4 -20.00% | -- -- | -- -- | -- -- | 0.37 -7.50% | -- -- | -- -- | -- -- | 0.54 +45.95% | -- -- | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0.5 -- | 0.27 -- | 0.58 -- | -- -- | 0.4 -20.00% | -0.21 -177.78% | 0.47 -18.97% | -- -- | 0.37 -7.50% | -- -- | -- -- | -- -- | 0.54 +45.95% | -- -- | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Takeda Pharmaceutical next quarter?What guidance did Takeda Pharmaceutical's management provide for the next earnings period?Did Takeda Pharmaceutical beat or miss consensus estimates last quarter?What is Takeda Pharmaceutical's gross profit margin?What were the key takeaways from Takeda Pharmaceutical’s earnings call?What is Takeda Pharmaceutical's latest dividend and current dividend yield?What factors drove the changes in Takeda Pharmaceutical's revenue and profit?What does Takeda Pharmaceutical do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
